[May 19, 2014]

Research and Markets: Tozadenant by Biotie (Parkinson's Disease) - Forecast and Market Analysis to 2022

Research and Markets (http://www.researchandmarkets.com/research/3f224r/tozadenant) has announced the addition of the "Tozadenant (Parkinson's Disease) - Forecast and Market Analysis to 2022" report to their offering.

Tozadenant is an adenosine 2A inhibitor in Phase IIb/III of development by Biotie. The compound was originally developed by Roche and subsequently licensed to Synosia, where it was further developed under the development code SYN115. License ownership was transferred to Biotie followinga merger with Synosia in January 2011. UCB and Biotie entered into a marketing partnership in 2010 for the development and commercialization of tozadenant.

Reasons to buy

• Understand and capitalize by identifying products that are most likely to ensure a robust return
• Stay ahead of the competition by understanding the changing competitive landscape for Parkinson's disease
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of Tozadenant performance
• Obtain sales forecast for Tozadenant from 2012-2022 in the top six countries (the US, France, Germany, Italy, Spain and the UK).

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

4 Disease Management

5 Competitive Assessment

6 Opportunity and Unmet Need

7 Pipeline Assessment

8 Tozadenant

9 Appendix

For more information visit http://www.researchandmarkets.com/research/3f224r/tozadenant

[ Back To TMCnet.com's Homepage ]